ROIV Roivant Sciences Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1635088 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY102.1%
TTM net income YoY7.9%
TTM EPS YoY-5.5%
Revenue 3-yr CAGR-16.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,358.1%
Net margin-838.2%
FCF margin-81.2%
EBITDA margin-1,352.0%
Returns
ROE-8.2%
ROA-6.9%
ROIC (approx.)-16.0%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets7.6%
Debt / equity0.00x
Current ratio15.56x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.11x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue-7.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-09-30 | 2026Q12026-06-30 | 2025Q4*2026-03-31 | 2025Q32025-12-31 | 2025Q22025-09-30 | 2025Q12025-06-30 | 2024Q4*2025-03-31 | 2024Q32024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $35.12M | $1.44M | $2.52M | $2.00M | $1.57M | $2.17M | $7.57M | $9.02M |
| Cost of revenue | $3.35M | — | — | — | $111,000 | — | — | — |
| Gross profit | $31.77M | — | — | — | $1.46M | — | — | — |
| R&D expense | $145.75M | $202.02M | $198.94M | $165.38M | $164.57M | $152.92M | $145.24M | $141.59M |
| SG&A expense | $154.08M | $165.53M | $158.25M | $175.07M | $143.12M | $134.02M | $147.09M | $141.54M |
| Operating income | -$268.05M | -$365.99M | $415.24M | -$339.15M | -$306.23M | -$284.92M | -$284.96M | -$274.38M |
| Pretax income | -$166.34M | -$294.56M | $454.10M | -$290.37M | -$159.04M | -$269.26M | -$203.05M | -$234.51M |
| Income tax | -$13.37M | -$3.96M | $98.35M | $23.33M | $7.00M | $4.65M | $49.32M | -$25.57M |
| Net income | -$191.62M | -$189.84M | $302.99M | -$265.89M | -$113.52M | -$223.35M | -$206.47M | $169.38M |
| EBITDA | -$267.44M | -$365.39M | $415.88M | -$338.46M | -$305.31M | -$283.82M | -$283.54M | -$271.46M |
| EPS (basic) | -0.27 | -0.26 | — | -0.38 | -0.17 | -0.33 | — | 0.23 |
| EPS (diluted) | -0.27 | -0.26 | — | -0.38 | -0.17 | -0.33 | — | 0.23 |
| Weighted avg. shares (diluted) | 722.75M | 720.78M | — | 696.86M | 680.95M | 680.29M | — | 722.72M |
| Balance sheet | ||||||||
| Cash & equivalents | $1.64B | $1.25B | $1.42B | $1.48B | $1.24B | $1.24B | $2.72B | $1.99B |
| Short-term investments | $2.57B | $2.59B | $2.87B | $3.05B | $3.15B | $3.26B | $2.17B | $3.16B |
| Receivables | — | — | — | — | — | — | — | $678,000 |
| Current assets | $4.36B | $4.74B | $5.17B | $4.66B | $4.51B | $4.62B | $5.00B | $5.36B |
| PP&E, net | $10.94M | $11.32M | $11.99M | $13.45M | $25.67M | $14.87M | $12.06M | $13.56M |
| Total assets | $4.98B | $5.31B | $5.71B | $5.23B | $5.06B | $5.03B | $5.44B | $5.79B |
| Current liabilities | $279.91M | $283.60M | $281.24M | $151.96M | $133.86M | $113.87M | $149.41M | $141.48M |
| Total liabilities | $380.10M | $384.62M | $416.27M | $251.14M | $257.14M | $216.70M | $249.74M | $256.38M |
| Shareholders' equity | $4.02B | $4.23B | $4.53B | $4.27B | $4.36B | $4.35B | $4.69B | $5.19B |
| Shares outstanding | 723.69M | 722.67M | 720.35M | 709.69M | 689.70M | 682.23M | 695.94M | 719.63M |
| Cash flow statement | ||||||||
| Operating cash flow | $594.42M | -$270.50M | -$163.82M | -$196.48M | -$185.66M | -$204.38M | -$172.56M | -$207.25M |
| Capital expenditure | $208,000 | $419,000 | $1.26M | -$4.93M | $7.85M | $4.04M | $811,000 | $1.83M |
| Free cash flow | $594.21M | -$270.92M | -$165.08M | -$191.55M | -$193.51M | -$208.42M | -$173.38M | -$209.08M |
| Investing cash flow | $42.54M | $281.26M | $173.49M | $109.47M | $120.42M | -$1.09B | $1.07B | $454.07M |
| Financing cash flow | -$249.21M | -$181.51M | -$68.78M | $328.19M | $62.59M | -$187.77M | -$177.15M | -$272.95M |
| Depreciation & amortization | $604,000 | $600,000 | $638,000 | $691,000 | $921,000 | $1.10M | $1.43M | $2.92M |
| Stock-based compensation | $79.30M | $83.34M | $77.17M | $105.00M | $81.82M | $82.18M | $83.49M | $83.68M |
| Share buybacks | $74.47M | $206.73M | — | $0 | $0 | $208.29M | $295.44M | $243.35M |
Free plan shows the latest 8 periods; Pro shows all 26 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.